{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:40:46Z","timestamp":1788486046737,"version":"build-2803163510"},"reference-count":88,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Coagulation testing has an important role in the diagnosis, monitoring, and therapeutic decision-making for patients with abnormal hemostasis. As the field of anticoagulation options has expanded, the introduction of direct oral anticoagulant (DOAC) drugs has provided an option for patients utilizing drugs that do not require routine monitoring. Patients on these drugs may still need coagulation testing for prognostic purposes, and there are a number of nuances to consider when performing coagulation testing in patients who are prescribed DOACs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>This document provides guidance on the tests that may or may not be impacted by the presence of DOACs in the blood. A discussion is provided about specific coagulation tests used and the impact of testing samples with a DOAC present. Options are presented to help mitigate the impact of DOACs on the testing. In addition, this document discusses how to test for and interpret DOAC concentrations in specific patient populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfaf155","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:54:40Z","timestamp":1757591680000},"page":"1675-1690","source":"Crossref","is-referenced-by-count":3,"title":["ADLM Guidance Document on Coagulation Testing in Patients Using Direct Oral Anticoagulants"],"prefix":"10.1093","volume":"10","author":[{"given":"Lindsay A L","family":"Bazydlo","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Virginia , Charlottesville, VA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9651-7754","authenticated-orcid":false,"given":"Maximo J","family":"Marin","sequence":"additional","affiliation":[{"name":"Department of Pathology, Immunology and Laboratory Medicine, University of Florida , Gainesville, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-5937","authenticated-orcid":false,"given":"Anna E","family":"Merrill","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Iowa , Iowa City, IA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise M","family":"Man","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Virginia , Charlottesville, VA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olajumoke O","family":"Oladipo","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Penn State Milton S. Hershey Medical Center , Hershey, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2329-2929","authenticated-orcid":false,"given":"Neil S","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Pathology, Immunology and Laboratory Medicine, University of Florida , Gainesville, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2025110500353535900_jfaf155-B1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.thromres.2011.12.014","article-title":"Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature","volume":"129","author":"Becattini","year":"2012","journal-title":"Thromb Res"},{"key":"2025110500353535900_jfaf155-B2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1592\/phco.31.12.1175","article-title":"Novel oral anticoagulants and their role in clinical practice","volume":"31","author":"Wittkowsky","year":"2011","journal-title":"Pharmacotherapy"},{"key":"2025110500353535900_jfaf155-B3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/hematology.2021000241","article-title":"Direct oral anticoagulant (DOAC) interference in hemostasis assays","volume":"2021","author":"Moser","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"Suppl 1","key":"2025110500353535900_jfaf155-B4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ijlh.12658","article-title":"The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue","volume":"39","author":"Adcock","year":"2017","journal-title":"Int J Lab Hematol"},{"key":"2025110500353535900_jfaf155-B5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/biomedicines9050445","article-title":"Laboratory monitoring of direct oral anticoagulants (DOACs)","volume":"9","author":"Dunois","year":"2021","journal-title":"Biomedicines"},{"issue":"Suppl 1","key":"2025110500353535900_jfaf155-B6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ijlh.12992","article-title":"An update on laboratory assessment for direct oral anticoagulants (DOACs)","volume":"41","author":"Gosselin","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"2025110500353535900_jfaf155-B7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International council for standardization in haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B8","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1055\/s-0038-1649507","article-title":"Mechanistic basis for the differential effects of rivaroxaban and apixaban on global tests of coagulation","volume":"2","author":"Kim","year":"2018","journal-title":"TH Open"},{"key":"2025110500353535900_jfaf155-B9","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 update of the international council for standardization in haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1515\/cclm-2013-0936","article-title":"Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests","volume":"52","author":"Eller","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"2025110500353535900_jfaf155-B11","author":"Gosselin"},{"key":"2025110500353535900_jfaf155-B12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.avsg.2023.08.004","article-title":"Impact of factor Xa inhibition on coagulation, platelet reactivity, and thrombosis in patients with peripheral artery disease","volume":"97","author":"Hall","year":"2023","journal-title":"Ann Vasc Surg"},{"key":"2025110500353535900_jfaf155-B13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.thromres.2019.10.007","article-title":"Effect of rivaroxaban and dabigatran on platelet functions: in vitro study","volume":"183","author":"Jourdi","year":"2019","journal-title":"Thromb Res"},{"key":"2025110500353535900_jfaf155-B14","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11239-017-1512-2","article-title":"Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner","volume":"44","author":"Vinholt","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"2025110500353535900_jfaf155-B15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1177\/1076029617734310","article-title":"First evidence: TRAP-induced platelet aggregation is reduced in patients receiving xabans","volume":"24","author":"Nehaj","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"2025110500353535900_jfaf155-B16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s11239-020-02093-9","article-title":"Edoxaban affects TRAP-dependent platelet aggregation","volume":"49","author":"Nehaj","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"2025110500353535900_jfaf155-B17","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/1076029617713871","article-title":"Thrombin receptor agonist peptide-induced platelet aggregation is reduced in patients receiving dabigatran","volume":"24","author":"Nehaj","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"2025110500353535900_jfaf155-B18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.thromres.2015.10.038","article-title":"TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran","volume":"138","author":"Olivier","year":"2016","journal-title":"Thromb Res"},{"key":"2025110500353535900_jfaf155-B19","doi-asserted-by":"crossref","first-page":"1076029620948585","DOI":"10.1177\/1076029620948585","article-title":"Impact of edoxaban on thrombin-dependent platelet aggregation","volume":"26","author":"Sokol","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"2025110500353535900_jfaf155-B20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1309\/AJCPY6G6ZITVKPVH","article-title":"The effect of dabigatran on select specialty coagulation assays","volume":"139","author":"Adcock","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"2025110500353535900_jfaf155-B21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/PAT.0000000000000252","article-title":"The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples","volume":"47","author":"Bonar","year":"2015","journal-title":"Pathology"},{"key":"2025110500353535900_jfaf155-B22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1160\/TH12-12-0898","article-title":"Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/rth2.12142","article-title":"Measurement of coagulation factors during rivaroxaban and apixaban treatment: results from two crossover trials","volume":"2","author":"Scheres","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pathol.2015.11.025","article-title":"The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples","volume":"48","author":"Bonar","year":"2016","journal-title":"Pathology"},{"key":"2025110500353535900_jfaf155-B25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2011.09.004","article-title":"Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban","volume":"129","author":"Gerotziafas","year":"2012","journal-title":"Thromb Res"},{"key":"2025110500353535900_jfaf155-B26","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1538-7836.2009.03555.x","article-title":"Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis","volume":"7","author":"Pengo","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B28","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the scientific and standardization committee for lupus anticoagulant\/antiphospholipid antibodies of the international society on thrombosis and haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B29","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/jth.14846","article-title":"Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Tripodi","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2015.05.001","article-title":"Direct oral anticoagulants (DOACs) in the laboratory: 2015 review","volume":"136","author":"Adcock","year":"2015","journal-title":"Thromb Res"},{"key":"2025110500353535900_jfaf155-B31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/ijlh.12528","article-title":"Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays","volume":"38","author":"Gosselin","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"2025110500353535900_jfaf155-B32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ijlh.13342","article-title":"Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory","volume":"43","author":"Siriez","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"2025110500353535900_jfaf155-B33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/jth.14667","article-title":"Recommendations for clinical laboratory testing for protein C deficiency, for the subcommittee on plasma coagulation inhibitors of the ISTH","volume":"18","author":"Cooper","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jth.15109","article-title":"Recommendations for clinical laboratory testing for protein s deficiency: communication from the SSC committee plasma coagulation inhibitors of the ISTH","volume":"19","author":"Marlar","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B35","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1111\/ijlh.12319","article-title":"The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays","volume":"37","author":"Kim","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"2025110500353535900_jfaf155-B36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5858\/arpa.2016-0616-OA","article-title":"Rivaroxaban causes missed diagnosis of protein s deficiency but not of activated protein C resistance (factor V Leiden)","volume":"142","author":"Maryamchik","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"2025110500353535900_jfaf155-B37","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.5858\/arpa.2019-0497-OA","article-title":"Apixaban does not interfere with protein S or activated protein C resistance (factor V Leiden) testing using aPTT-based methods","volume":"144","author":"Maryamchik","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"2025110500353535900_jfaf155-B38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1160\/TH15-12-0918","article-title":"Protein s testing in patients with protein S deficiency, factor V Leiden, and rivaroxaban by North American specialized coagulation laboratories","volume":"116","author":"Smock","year":"2016","journal-title":"Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B39","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1515\/cclm-2019-0650","article-title":"DOAC-remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients","volume":"58","author":"Kopytek","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2025110500353535900_jfaf155-B40","first-page":"666","article-title":"The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden","volume":"13","author":"Gessoni","year":"2015","journal-title":"Blood Transfus"},{"key":"2025110500353535900_jfaf155-B41","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/jth.14532","article-title":"Recommendations for clinical laboratory testing of activated protein C resistance; communication from the SSC of the ISTH","volume":"17","author":"Moore","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B42","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","article-title":"Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature","volume":"130","author":"Douxfils","year":"2012","journal-title":"Thromb Res"},{"key":"2025110500353535900_jfaf155-B43","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1309\/AJCPAU7OQM0SRPZQ","article-title":"Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy","volume":"137","author":"Avecilla","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"2025110500353535900_jfaf155-B44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/ajcp\/aqab135","article-title":"From activated partial thromboplastin time to antifactor Xa and back again","volume":"157","author":"May","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"2025110500353535900_jfaf155-B45","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/jalm\/jfaa084","article-title":"A novel laboratory assay to monitor unfractionated heparin dosing in patients taking apixaban prior to hospital admission","volume":"6","author":"Strickland","year":"2021","journal-title":"J Appl Lab Med"},{"key":"2025110500353535900_jfaf155-B46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12959-017-0160-2","article-title":"Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation","volume":"16","author":"Henskens","year":"2018","journal-title":"Thromb J"},{"key":"2025110500353535900_jfaf155-B47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/ijlh.12744","article-title":"Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM)","volume":"40","author":"Seyve","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"2025110500353535900_jfaf155-B48","doi-asserted-by":"crossref","first-page":"23094990211042674","DOI":"10.1177\/23094990211042674","article-title":"Application of thromboelastography in comparing coagulation difference of rivaroxaban and enoxaparin for thromboprophylaxis after total hip arthroplasty","volume":"29","author":"Bai","year":"2021","journal-title":"J Orthop Surg (Hong Kong)"},{"key":"2025110500353535900_jfaf155-B49","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/ALN.0000000000003061","article-title":"Correlation of thromboelastography with apparent rivaroxaban concentration: has point-of-care testing improved?","volume":"132","author":"Myers","year":"2020","journal-title":"Anesthesiology"},{"key":"2025110500353535900_jfaf155-B50","first-page":"47-53","article-title":"Effects of direct oral anticoagulants on thromboelastographic parameters and fibrin clot properties in patients with venous thromboembolism","volume":"71","author":"Kopytek","year":"2020","journal-title":"J Physiol Pharmacol"},{"key":"2025110500353535900_jfaf155-B51","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1055\/s-0037-1599157","article-title":"Point-of-care coagulation tests monitoring of direct oral anticoagulants and their reversal therapy: state of the art","volume":"43","author":"Iapichino","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"2025110500353535900_jfaf155-B52","doi-asserted-by":"crossref","first-page":"10760296221138297","DOI":"10.1177\/10760296221138297","article-title":"Differential neutralization of apixaban, betrixaban, edoxaban, and rivaroxaban by andexanet alfa as measured by whole blood thromboelastographic analysis","volume":"28","author":"Mehrotra","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"2025110500353535900_jfaf155-B53","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.4960170704","article-title":"The use of activated clotting times to monitor heparin therapy during and after interventional procedures","volume":"17","author":"Bowers","year":"1994","journal-title":"Clin Cardiol"},{"key":"2025110500353535900_jfaf155-B54","volume-title":"Coagulation, limited. Cgl-c 2021. Activated clotting time (ACT)","author":"Kaur","year":"2021"},{"key":"2025110500353535900_jfaf155-B55","doi-asserted-by":"crossref","first-page":"106994","DOI":"10.1016\/j.vph.2022.106994","article-title":"The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time","volume":"144","author":"Negro","year":"2022","journal-title":"Vascul Pharmacol"},{"key":"2025110500353535900_jfaf155-B56","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jth.12649","article-title":"Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays","volume":"12","author":"Hillarp","year":"2014","journal-title":"J Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B57","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1111\/ijlh.13743","article-title":"Effect of DOAC-remove on coagulation screening assays in samples from patients receiving oral or parenteral anticoagulation","volume":"44","author":"Al-Qawzai","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"2025110500353535900_jfaf155-B58","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ijlh.12950","article-title":"Influence of DOAC stop on coagulation assays in samples from patients on rivaroxaban or apixaban","volume":"41","author":"Platton","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"2025110500353535900_jfaf155-B59","author":"Haematex"},{"key":"2025110500353535900_jfaf155-B60","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ajcp\/aqab149","article-title":"Performance characteristics of DOAC-remove for neutralization of the effects of apixaban and rivaroxaban in lupus anticoagulant assays","volume":"157","author":"Skaugen","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"2025110500353535900_jfaf155-B61","doi-asserted-by":"crossref","first-page":"1076029619872556","DOI":"10.1177\/1076029619872556","article-title":"Evaluation of the DOAC-Stop procedure by LC-MS\/MS assays for determining the residual activity of dabigatran, rivaroxaban, and apixaban","volume":"25","author":"Slavik","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"2025110500353535900_jfaf155-B62","doi-asserted-by":"crossref","first-page":"e12633","DOI":"10.1002\/rth2.12633","article-title":"Direct oral anticoagulant removal by a DOAC filter: impact on lupus anticoagulant testing\u2014evaluation on spiked and patient samples","volume":"6","author":"Linskens","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B63","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"2025110500353535900_jfaf155-B64","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"key":"2025110500353535900_jfaf155-B65","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/ijlh.12807","article-title":"The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays","volume":"40","author":"Jacquemin","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"2025110500353535900_jfaf155-B66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12959-023-00501-7","article-title":"The methods for removal of direct oral anticoagulants and heparins to improve the monitoring of hemostasis: a narrative literature review","volume":"21","author":"Frackiewicz","year":"2023","journal-title":"Thromb J"},{"key":"2025110500353535900_jfaf155-B67","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1515\/dx-2020-0119","article-title":"Bringing the clinical laboratory into the strategy to advance diagnostic excellence","volume":"8","author":"Lubin","year":"2021","journal-title":"Diagnosis (Berl)"},{"key":"2025110500353535900_jfaf155-B68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/biomedicines9030262","article-title":"Updates in anticoagulation therapy monitoring","volume":"9","author":"McRae","year":"2021","journal-title":"Biomedicines"},{"key":"2025110500353535900_jfaf155-B69","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025110500353535900_jfaf155-B70","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","article-title":"Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review","volume":"2","author":"Eikelboom","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2025110500353535900_jfaf155-B71","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1515\/cclm-2014-0767","article-title":"Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?","volume":"53","author":"Lippi","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"2025110500353535900_jfaf155-B72","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1515\/CCLM.2011.134","article-title":"Laboratory assessment of new anticoagulants","volume":"49","author":"Samama","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"2025110500353535900_jfaf155-B73","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B74","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/CIRCULATIONAHA.116.022307","article-title":"Urgent need to measure effects of direct oral anticoagulants","volume":"134","author":"Weitz","year":"2016","journal-title":"Circulation"},{"key":"2025110500353535900_jfaf155-B75","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/s-0041-1723770","article-title":"Direct oral anticoagulants plasma levels measurement: clinical usefulness from trials and real-world data","volume":"47","author":"Renon","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"2025110500353535900_jfaf155-B76","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/phar.1884","article-title":"Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know","volume":"37","author":"Conway","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2025110500353535900_jfaf155-B77","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B78","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40495-020-00232-7","article-title":"Overview and practical application of coagulation assays in managing anticoagulation with direct oral anticoagulants (DOACs)","volume":"6","author":"Rimsans","year":"2020","journal-title":"Curr Pharmacol Rep"},{"key":"2025110500353535900_jfaf155-B79","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/jth.12702","article-title":"Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography\u2014tandem mass spectrometry (UPLC-MS\/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants","volume":"12","author":"Schmitz","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"Part B","key":"2025110500353535900_jfaf155-B80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.trac.2016.01.029","article-title":"Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?","volume":"84","author":"Douxfils","year":"2016","journal-title":"TrAC Trends in Analytical Chemistry"},{"key":"2025110500353535900_jfaf155-B81","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/hematology.2019000027","article-title":"Direct oral anticoagulant monitoring: what laboratory tests are available to guide us?","volume":"2019","author":"Sarode","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2025110500353535900_jfaf155-B82","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.transci.2016.05.016","article-title":"An update on laboratory measurements of dabigatran: smart specific and calibrated dedicated assays for measuring anti-IIa activity in plasma","volume":"54","author":"Amiral","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"2025110500353535900_jfaf155-B83","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.thromres.2014.12.021","article-title":"Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS\/MS in human volunteers on dialysis","volume":"135","author":"Schmohl","year":"2015","journal-title":"Thromb Res"},{"key":"2025110500353535900_jfaf155-B84","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1160\/TH13-03-0202","article-title":"Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS\/MS for the therapeutic monitoring of patients treated with dabigatran etexilate","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"2025110500353535900_jfaf155-B86","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bcp.12106","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects","volume":"76","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2025110500353535900_jfaf155-B87","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2025110500353535900_jfaf155-B88","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jtha.2024.07.009","article-title":"Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"22","author":"Levy","year":"2024","journal-title":"J Thromb Haemost"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/6\/1675\/65172505\/jfaf155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/6\/1675\/65172505\/jfaf155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:35:54Z","timestamp":1762320954000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/10\/6\/1675\/8296999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":88,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfaf155","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,11]]}}}